NASDAQ:MTNB - Matinas Biopharma Stock Price, News & Analysis

$0.68
-0.02 (-2.86 %)
(As of 08/20/2019 02:12 AM ET)
Today's Range
$0.67
Now: $0.68
$0.73
50-Day Range
$0.6508
MA: $0.77
$0.90
52-Week Range
$0.37
Now: $0.68
$1.50
Volume523,400 shs
Average Volume927,585 shs
Market Capitalization$110.44 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MTNB
CUSIPN/A
CIKN/A
Phone908-443-1860

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$110.44 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.


Matinas Biopharma (NASDAQ:MTNB) Frequently Asked Questions

What is Matinas Biopharma's stock symbol?

Matinas Biopharma trades on the NASDAQ under the ticker symbol "MTNB."

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NASDAQ:MTNB) released its earnings results on Tuesday, August, 13th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm earned $0.09 million during the quarter, compared to the consensus estimate of $0.06 million. View Matinas Biopharma's Earnings History.

When is Matinas Biopharma's next earnings date?

Matinas Biopharma is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Matinas Biopharma.

What is the consensus analysts' recommendation for Matinas Biopharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas Biopharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas Biopharma.

Has Matinas Biopharma been receiving favorable news coverage?

News articles about MTNB stock have been trending negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Matinas Biopharma earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Matinas Biopharma.

Who are some of Matinas Biopharma's key competitors?

What other stocks do shareholders of Matinas Biopharma own?

Who are Matinas Biopharma's key executives?

Matinas Biopharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)
  • Mr. Keith A. Kucinski CPA, Chief Financial Officer (Age 48)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain

How do I buy shares of Matinas Biopharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas Biopharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.68.

How big of a company is Matinas Biopharma?

Matinas Biopharma has a market capitalization of $110.44 million. View Additional Information About Matinas Biopharma.

What is Matinas Biopharma's official website?

The official website for Matinas Biopharma is http://www.matinasbiopharma.com/.

How can I contact Matinas Biopharma?

The company can be reached via phone at 908-443-1860.


MarketBeat Community Rating for Matinas Biopharma (NASDAQ MTNB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about Matinas Biopharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel